Embecta Corp
NASDAQ:EMBC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.28
19.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Embecta Corp
NASDAQ:EMBC
|
721.3m USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.5T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
32.2B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
35.1B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
123.4B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.2B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
44.7B CNY |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6.1B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.5B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.9B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Embecta Corp
Glance View
Embecta Corp. emerges as a notable player in the medical technology landscape, carved out as an independent entity after parting ways from Becton, Dickinson and Company. The separation was driven by a vision to concentrate efforts more precisely on the specialized field of diabetes management. Embecta inherits a rich heritage of innovation and expertise, focusing on the development and distribution of advanced medical devices designed to assist individuals in managing diabetes. Their primary offering revolves around insulin delivery systems, which are critical for the day-to-day management of diabetes by patients worldwide. Embecta’s capabilities are further augmented by their robust research and development wing, which relentlessly pursues advancements in technology to improve patient outcomes and enhance user experience. The company’s business model hinges on a combination of product sales and the establishment of lasting relationships with healthcare providers and patients. By ensuring a steady pipeline of disposable products and innovative technologies, Embecta not only generates recurring revenue through its insulin delivery solutions but also positions itself as a leader in the field of diabetic care. Their strategy encompasses a strong distribution network that reaches global markets, leveraging partnerships, acquisitions, and direct sales strategies to expand their footprint. With an eye on the future, Embecta is keenly aware of the growing prevalence of diabetes globally and continues to innovate and adapt, ensuring that their products meet the evolving needs of their end-users.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Embecta Corp is 8.8%, which is above its 3-year median of 7%.
Over the last 3 years, Embecta Corp’s Net Margin has decreased from 19.8% to 8.8%. During this period, it reached a low of 4.2% on Jun 30, 2023 and a high of 19.8% on Sep 30, 2022.